|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's Range||0.3433 - 3.4880|
|52 Week Range||0.3433 - 8.1980|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2023 - May 15, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for GX1N.DU
Marker Therapeutics agreed to a $25 million stock purchase deal with Chicago-based institutional investor Lincoln Park Capital Fund to help advance clinical trials for some of its immunotherapy products.
HOUSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company has entered into a Common Stock Purchase Agreement (the "Agreement") for up to $25 million with Lincoln Park Capital Fund ("LPC"), a Chicago-based institutional investor and long-term
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...